Mesoblast limited (MESO) PT Set at $14.00 by Maxim Group
Mesoblast limited (NASDAQ:MESO) received a $14.00 price target from equities researchers at Maxim Group in a research note issued on Thursday. The firm presently has a “buy” rating on the stock. Maxim Group’s price target suggests a potential upside of 77.22% from the company’s previous close.
Several other research analysts have also issued reports on MESO. Zacks Investment Research upgraded Mesoblast limited from a “sell” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Tuesday. Scotiabank reiterated a “hold” rating and set a $8.50 target price on shares of Mesoblast limited in a report on Monday, April 3rd.
Shares of Mesoblast limited (NASDAQ:MESO) traded down 8.46% during mid-day trading on Thursday, hitting $7.90. The stock had a trading volume of 88,883 shares. The firm’s 50-day moving average price is $10.47 and its 200 day moving average price is $7.23. The stock’s market cap is $601.14 million. Mesoblast limited has a 12-month low of $3.50 and a 12-month high of $12.50.
TRADEMARK VIOLATION NOTICE: “Mesoblast limited (MESO) PT Set at $14.00 by Maxim Group” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/25/mesoblast-limited-meso-pt-set-at-14-00-by-maxim-group.html.
Large investors have recently modified their holdings of the company. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Mesoblast limited by 4.6% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 25,890 shares of the company’s stock valued at $139,000 after buying an additional 1,145 shares during the period. Princeton Capital Management Inc. boosted its stake in Mesoblast limited by 15.5% in the first quarter. Princeton Capital Management Inc. now owns 155,700 shares of the company’s stock valued at $1,398,000 after buying an additional 20,945 shares during the last quarter. Finally, Morgan Stanley boosted its stake in Mesoblast limited by 1,999.0% in the first quarter. Morgan Stanley now owns 20,990 shares of the company’s stock valued at $189,000 after buying an additional 19,990 shares during the last quarter. Institutional investors own 3.14% of the company’s stock.
Mesoblast limited Company Profile
Receive News & Ratings for Mesoblast limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast limited and related companies with MarketBeat.com's FREE daily email newsletter.